Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC
This article was originally published in The Pink Sheet Daily
Executive Summary
Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.
You may also be interested in...
As VC Investments Rebound In Q2, Skepticism Lingers
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
Financings Of The Fortnight: Is Venture Capital's Glass Half-Full Or Half-Empty?
Fundraising successes by Trevena, Sunesis, Calithera and iPierian highlight the last two weeks' action.
As Some VCs Run On Empty, Others Are Topping Off The Tank
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.